Navigation Links
Renhuang Begins Trading on NYSE Amex
Date:7/7/2010

HARBIN, China, July 7 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (NYSE Amex: CBP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that, commencing on July 2, 2010, its common stock is trading on the NYSE Amex Market under the ticker symbol "CBP".

On this occasion, Mr. Shaoming Li, Chairman of the Board, Chief Executive Officer and President of Renhuang Pharmaceuticals, Inc. made the following statement:

"We would like to congratulate our shareholders and welcome them to one of the world's largest and most prestigious exchanges. Those shareholders who have been with us for some time have seen Renhuang grow into a major presence in botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in China. We have shown revenue growth of 24.5% CAGR in the last three years and have launched Banlangen Granules, Compound Honeysuckle Granules, and Qing Re Jie Du Oral Liquid in 2009 and 2010. The Company will launch Compound Schisandra Tablets in July 2010 and Ginseng and Deer Antler Extract in August 2010. The Company continues to play a crucial role in introducing safe and effective botanical drugs, including its leading Siberian Ginseng (Acanthopanax) series, biopharmaceuticals and OTC traditional Chinese medicines, with a key focus on the development of botanical anti-depression and nerve-regulation products.

"In addition, the listing of our common stock on the NYSE Amex is an important part of our overall future growth strategy as well. I would like to outline some of the ways in which our prospects are enhanced by this milestone event.

    -- First, we are committed to life as a responsible US public company and
       the standards of disclosure, corporate governance and overall
       transparency for companies listed on NYSE AMEX are among the highest if
       not the highest in the world. We welcome the opportunity to comply with
       these standards and believe our compliance will attract new and more
       discerning shareholders to our roster

    -- Second, this large and liquid exchange greatly enhances the prospects
       for buyers of any new shares we may issue of a deeper market for any
       enhanced share count. Since we believe we will have many opportunities
       to put capital to good use in the future through product expansion, new
       product development, product marketing, enhanced R&D and growth by
       acquisition, we believe our listing on the senior exchange is likely to
       lead to a partnership with a wider group of shareholders over time and
       will help broaden our visibility in the U.S. capital markets

"We would also like to take this opportunity to thank all the other stakeholders in the fortunes of Renhuang - our management team, dedicated employees, and loyal customers - for their ongoing support. We believe that this listing enhances their prospects of enjoying further success with us in the future."

ABOUT RENHUANG PHARMACEUTICALS, INC.

Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. Company Website: http://www.renhuang.com .

Safe Harbor Statement

This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's perceived benefits from listing on a senior exchange, ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.

    For more information, please contact:

    Company Contact:
     Renhuang Pharmaceuticals, Inc.
     Ms. Portia Tan, IR Contact
     Tel:   +86-451-8260-2162
     Email: ir@renhuang.com

    CCG Investor Relations:
     Mr. Mark Collinson, Partner
     Tel:   +1-310-954-1343 (Los Angeles)
     Email: mark.collinson@ccgir.com
     Web:   http://www.ccgirasia.com

     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915 (New York)
     Email: crocker.coulson@ccgir.com


'/>"/>
SOURCE Renhuang Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Renhuang Pharmaceuticals Receives Approval to List on the NYSE Amex
2. Renhuang Pharmaceuticals Exhibits Siberian Ginseng Products at the 21st China Harbin International Economic and Trade Fair
3. Renhuang to Launch New Bio-pharmaceutical Product - Ginseng and Deer Antler Extract
4. Renhuang to Launch New All-Natural Anti-depressant and Nerve Regulation Product - Compound Schisandra Tablets
5. Renhuang Wins Bid to Supply All-Natural Products to Guangzhou Military District
6. Renhuang Schedules Conference Call to Discuss FY 2010 Second Quarter Results
7. Renhuang Appoints PricewaterhouseCoopers to Develop a SOX 404 Compliance Program
8. Renhuang Announces Successful Preliminary Review of Its Patent Application for Schisandra Total Lignin Extraction Method
9. Renhuang Pharmaceuticals Exhibits All-Natural Products at the 107th China Import and Export Fair
10. Renhuang Elected as Deputy Chair Unit of Heilongjiang Medical Association
11. Renhuang Pharmaceuticals Announces Plans to Introduce Qing Re Jie Du Oral Liquid
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... YORK , Feb. 23, 2017  The ... 330.6 million by 2021 from USD 275.9 million ... Read the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... increasing spending on pharmaceutical R&D, and growth in ... driving the market growth for particle counters. On ...
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... provides drug pricing data and benchmarks in the global Autism Spectrum ... What are the key drugs marketed for Autism ...
(Date:2/23/2017)... CITY, Calif., Feb. 23, 2017 Nevro Corp. (NYSE: ... evidence-based solutions for the treatment of chronic pain, today reported ... December 31, 2016. 2016 Accomplishment & Highlights: ... full year 2016, an increase of 228% as reported, over ... for 2016, an increase of 612% over the prior year ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... WHAT: ... networking and recognition opportunities as well as advocacy for the state and region‘s ... on February 23. The Council's Innovation Forecast event highlights innovation throughout the ...
(Date:2/24/2017)... ... , ... With millions of Americans and people worldwide struggling ... are aware of our options and are empowered with strength and information throughout ... its newest edition of "Vision and Hearing" in USA Today, that will educate ...
(Date:2/24/2017)... , ... February 24, 2017 , ... Yisrayl Hawkins, Pastor ... on Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement when ... generation. He explains that the Bible details the current times so plainly that ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations to ... Elite division on February 12th. Ms. Esparza qualified into this prestigious status ... competition held in Las Vegas, Nevada. Frida is one of approximately 25 gymnasts ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... the La Gorce Country Club in Miami Beach to host its Swirl: Miami ...
Breaking Medicine News(10 mins):